PNC Financial Services Group Inc. Decreases Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

PNC Financial Services Group Inc. lowered its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 32.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,400 shares of the life sciences company's stock after selling 6,373 shares during the period. PNC Financial Services Group Inc.'s holdings in Illumina were worth $1,063,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the stock. Capital World Investors boosted its holdings in Illumina by 408.6% in the fourth quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock valued at $2,408,721,000 after acquiring an additional 14,481,232 shares in the last quarter. WCM Investment Management LLC boosted its holdings in Illumina by 1.2% in the first quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company's stock valued at $334,321,000 after acquiring an additional 49,156 shares in the last quarter. Brown Advisory Inc. boosted its holdings in Illumina by 52.1% in the first quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company's stock valued at $230,818,000 after acquiring an additional 996,589 shares in the last quarter. Northern Trust Corp boosted its holdings in Illumina by 26.9% in the fourth quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company's stock valued at $220,882,000 after acquiring an additional 349,878 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Illumina by 2.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,292,407 shares of the life sciences company's stock valued at $172,704,000 after acquiring an additional 32,270 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Stock Up 1.3%

Shares of ILMN traded up $1.34 during trading hours on Friday, hitting $101.43. The company had a trading volume of 250,605 shares, compared to its average volume of 2,359,836. The firm has a fifty day moving average price of $96.46 and a 200-day moving average price of $90.38. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The stock has a market capitalization of $15.59 billion, a price-to-earnings ratio of 12.86, a P/E/G ratio of 2.27 and a beta of 1.37. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%. The firm had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the firm earned $0.36 EPS. Illumina's quarterly revenue was down 4.8% compared to the same quarter last year. On average, equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent analyst reports. Evercore ISI lifted their price target on shares of Illumina from $116.00 to $128.00 and gave the company an "outperform" rating in a report on Tuesday, July 8th. Canaccord Genuity Group raised their price objective on Illumina from $99.00 to $105.00 and gave the company a "hold" rating in a research report on Friday, August 1st. Stephens set a $110.00 price objective on Illumina and gave the company an "overweight" rating in a research report on Monday, August 4th. Guggenheim lowered their price objective on Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, Citigroup lowered Illumina from a "hold" rating to a "strong sell" rating and lowered their price objective for the company from $85.00 to $80.00 in a research report on Wednesday, July 9th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $124.58.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.